Patent ID: 6172061
Filing Date: 2001-01-09
Classification: A61K,A61P,C07C,C07D

Abstract:
A pharmaceutical composition for antagonizing CCR5 which comprises a compound of the formula: ##STR38##whereinR.sup.1 is an optionally substituted 5- to 6-membered ring;W is a divalent group of the formula: ##STR39##wherein the ring A is an optionally substituted 5- to 6-membered aromatic ring, X is an optionally substituted carbon atom, an optionally substituted nitrogen atom, sulfur atom or oxygen atom, and the ring B is an optionally substituted 5- to 7-membered ring; Z is a chemical bond or a divalent group; R.sup.2 is (1) an optionally substituted amino group in which a nitrogen atom may form a quaternary ammonium, (2) an optionally substituted nitrogen-containing heterocyclic ring group which may contain a sulfur atom or an oxygen atom as ring constituting atoms and wherein a nitrogen atom may form a quaternary ammonium, (3) a group binding through a sulfur atom or (4) a group of the formula: ##STR40##wherein k is 0 or 1, and when k is 0, a phosphorus atom may form a phosphonium; and R.sup.5' and R.sup.6' are independently an optionally substituted hydrocarbon group, an optionally substituted hydroxy group or an optionally substituted amino group, and R.sup.5' and R.sup.6' may bind to each other to form a cyclic group together with the adjacent phosphorus atom, or a salt thereof.